FK506 in the treatment of inflammatory skin disease: promises and perspectives
- 1 March 1996
- journal article
- review article
- Published by Elsevier in Immunology Today
- Vol. 17 (3), 106-108
- https://doi.org/10.1016/0167-5699(96)80599-8
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapyClinical and Experimental Immunology, 1995
- Tacrolimus ointment for atopic dermatitisThe Lancet, 1994
- Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pigArchives of Dermatological Research, 1994
- The interleukin-8 receptor: a potential target for antipsoriatic therapy?European Journal of Pharmacology, 1994
- Differential Inhibition of Cutaneous T-Cell-Mediated Reactions and Epidermal Cell Proliferation by Cyclosporin A, FK-506, and RapamycinJournal of Investigative Dermatology, 1994
- Role of lnterleukin-8 Receptor in SkinInternational Archives of Allergy and Immunology, 1994
- Anti-Inflammatory Effect of FK-506 on Human Skin Mast CellsJournal of Investigative Dermatology, 1992
- Interleukin-8 Stimulates Calcium Transients and Promotes Epidermal Cell ProliferationJournal of Investigative Dermatology, 1992
- Immunosuppressive Macrolides of the Type FK 506: A Novel Class of Topical Agents for Treatment of Skin Diseases?Journal of Investigative Dermatology, 1992
- The mechanism of action of cyclosporin A and FK506Immunology Today, 1992